References
1. Lobzin Yu.V., Kryukov E.V., Zhdanov K.V., et al. The system of detection and medical support for HBV and HCV infections among conscripts (on the model of the Black Sea Fleet). Gepatologiya [Hepatology]. 2003; (1): 6-10. (in Russian)
2. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17 (2): 107-15.
3. Garmaeva T.Ts. Viral hepatitis B and C in patients with blood system diseases. Authoabstract of Diss. Moscow; 2012. (in Russian)
4. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology. 2002; 36 (5, Suppl 1): S237-44.
5. Rossotti R., Travi G., Pazzi A., et aL. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/ NS4A inhibitor-based treatment. A case report. J Hepatol. 2015; 62 (1): 234-7.
6. Carrier P., Jaccard A., Jacques J., et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int. 2015; 35 (10): 2222-7.
7. Peveling-Oberhag J., Arcaini L., Bankov K., et al. The antilymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis. J Viral Hepat. 2016; 23 (7): 536-44.
8. Sulkowski M.S., Wasserman R., Brooks L., et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J ViraL Hepat. 2004; 11 (3): 243-50.
9. Jacobson I.M., McHutchison J.G., Dusheiko G., et aL. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364 (25): 2405-16.
10. Sherman K.E., Flamm S.L., Afdhal N.H., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011; 365 (11): 1014-24.
11. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364 (13): 1195206.
12. Soota K., MaLiakkaL B. Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infection. World J Gastroenterol. 2014; 20 (43): 16 184-90.
13. Dieterich D.T., Spivak J.L. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis. 2003; 37 (4): 533-41.
14. KowdLey K.V. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol. 2005; 39 (1 Suppl): S3-8.
15. Villar L.M., Del Campo J.A., Ranchal I., et al. Association between vitamin D and hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2013; 19 (35): 5917-24.
16. Dietvorst M.H.P., van Wijngaarden P., de Man R.A. Autoimmune haemolytic anaemia due to chronic hepatitis C virus infection treated with prednisone, pegylated interferon and ribavirin. Neth J Med. 2009; 67 (3): 109-10.
17. Basu A., Nidhi D., Mehebubar R., et al. Treatment of autoimmune haemolytic anaemia with hepatitis C virus-A real challenge. Sri Lankan J Infect Dis. 2016; 6. doi: 10.4038/sljid.v6i2.8115.
18. Rauff B., Idrees M., Shah S.A.R., et al. Hepatitis associated aplastic anemia: a review. Virol J. 2011; 8: 87.
19. Roomer R., Hansen B.E., Janssen H.L.A., de Knegt R.J. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2010; 52 (4): 1225-31.
20. Ramos-Casals M., Garcia-Carrasco M., Lopez-Medrano F., et al. Severe autoimmune cytopenias in treatment-naive hepatitis C virus infection: clinicaL description of 35 cases. Medicine (Baltimore). 2003; 82 (2): 87-96.
21. Abou El Azm A.R., El-Bate H., Abo-Ali L., et al. Correlation of viral load with bone marrow and hematological changes in pale patients with chronic hepatitis C virus. Arch Virol. 2012; 157 (8): 1579-86.
22. Sharvadze L., Karchava M., Bolokadze N., et al. Safety and efficacy of systematic administration of Filgrastim to prevent neutropenia and infections in patient with hepatitis C. Georgian Med News 2009; 175: 32-5.
23. Chabert A., Hamzeh-Cognasse H., Pozzetto B., et al. Human platelets and their capacity of binding viruses: meaning and challenges? BMC Immunol. 2015; 16: 26.
24. Assinger A. Platelets and infection - an emerging role of platelets in viral infection. Front Immunol. 2014; 5: 1-12. doi: 10.3389/fimmu.2014.00649.
25. Roomer R., Hansen B.E., Janssen H.L.A., de Knegt R.J. Thrombocytopenia and the risk of bleeding during treatment with peginter-feron alfa and ribavirin for chronic hepatitis C. J Hepatol. 2010; 53 (3): 455-9.
26. Giannini E.G. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006; 23 (8): 1055-65.
27. Louie K.S., Micallef J.M., Pimenta J.M., Forssen U.M. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. J Viral Hepat. 2011; 18 (1): 1-7.
28. Adinolfi L.E., Giordano M.G., Andreana A., et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol. 2001; 113 (3): 590-5.
29. Panzer S., Seel E., Brunner M., et al. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol. 2006; 77 (6): 513-7.
30. Aref S., Sleem T., El Menshawy N., et al. Antiplatelet antibodies contribute to thrombocytopenia associated with chronic hepatitis C virus infection. Hematology. 2009; 14 (5): 277-81.
31. Garcia-Suarez J., Burgaleta C., Hernanz N., et al. HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy. Br J Haematol. 2000; 110 (1): 98-103.
32. Sung, H., Chang, M., Saab, S. Management of hepatitis C antiviral therapy adverse effects. Curr Hepat Rep. 2011; 10 (1): 33-40.
33. Burness C.B. Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C. Drugs. 2014; 74 (16): 1961-71.
34. Terrault N.A., Hassanein T., Howell C.D., et al. Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol. 2014; 61 (6): 1253-9.
35. Buccoliero G., Urbano T., Massa P., et al. Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis C virus infection: a new option for clinicians? New Microbiol. 2014; 37 (1): 97-101.
36. Moussa M.M., Mowafy N. Preoperative use of romiplostim in thrombocytopenic patients with chronic hepatitis C and liver cirrhosis. J Gastroenterol Hepatol. 2013; 28 (2): 335-41.
37. Lawitz E.J., Hepburn M.J., Casey T.J. A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol. 2004; 99 (12): 2359-64.
38. Dahal S., Upadhyay S., Banjade R., et al. Thrombocytopenia in patients with chronic hepatitis C virus infection. Mediterr J Hematol Infect Dis. 2017; 9 (1). doi: 10.4084/MJHID.2017.019.
39. Papakonstantinou I., Poulakidas I. Monoclonal antibody Ritux-imab for severe immune thrombocytopenia after pegylated interferon for hepatitis C infection. Hippokratia. 2014; 18 (4): 370-2.
40. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015; 63 (1): 199-236.
41. Sulkowski M.S., Shiffman M.L., Afdhal N.H., et al. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology 2010; 139 (5): 1602-11.
42. Ataei B., Hashemipour M., Kassaian N., et al. Prevalence of anti HCV infection in patients with beta-thalassemia in Isfahan-Iran. Int J Prev Med. 2012; 3 (1): S118-23.
43. Hassan M., Hasan S., Giday S., et al. Hepatitis C virus in sickle cell disease. J Natl Med Assoc. 2003; 95 (10): 939-42.
44. Papatheodoridis G.V., Papakonstantinou E., Andrioti E., et al. Thrombotic risk factors and extent of liver fibrosis in chronic viral hepatitis. Gut. 2003; 52 (3): 404-9.
45. Wang C.C., Chang C.T., Lin C.L., et al. Hepatitis C virus infection associated with an increased risk of deep vein thrombosis: a population-based cohort study. Medicine (Baltimore). 2015; 94 (38): e1585.
46. Di Bisceglie A.M., Axiotis C.A., Hoofnagle J.H., Bacon B.R. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 1992; 102 (6): 2108-13.
47. Price L., Kowdley K.V. The role of iron in the pathophysiology and treatment of chronic hepatitis C. Can J Gastroenterol. 2009; 23 (12): 822-8.
48. Fujita N., Sugimoto R., Takeo M., et al. Hepcidin expression in the liver: relatively low level in patients with chronic hepatitis C. Mol Med Camb Mass. 2007; 13 (1-2): 97-104.
49. Kohjima M., Yoshimoto T., Enjoji M., et al. Hepcidin/ferroportin expression levels involve efficacy of pegylated-interferon plus ribavirin in hepatitis C virus-infected liver. World J Gastroenterol. 2015; 21 (11): 3291-9.
50. Desai T.K., Jamil L.H., Balasubramaniam M., et al. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: a meta-analysis of six prospective randomized controlled trials. Dig Dis Sci. 2008; 53 (3): 815-22.
51. Sebastiani G., Tempesta D., Alberti A. Hepatic iron overload is common in chronic hepatitis B and is more severe in patients coinfected with hepatitis D virus. J Viral Hepat. 2012; 19 (2): e170-6.